DED

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Retrieved on: 
목요일, 5월 2, 2024
FDA, Hydrus, MIGS, Telecanthus, Nature, Refractive surgery, News, Research, Depreciation, Cataract, Security (finance), IOP, DED, Webcast, Growth, Environment, District court, Patent, Intraocular pressure, Patient, Court, Society, Judgement, Glaucoma, Alcon, Ciclosporin, Standard of care, GAAP, Pharmaceutical industry

Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.

Key Points: 
  • Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.
  • The jury found that Sight Sciences’ asserted patents were willfully infringed, and awarded monetary damages for past infringement.
  • Sight Sciences reaffirms revenue guidance expectations for full year 2024 of approximately $81.0 million to $85.0 million, representing growth of approximately 0% to 5% growth compared to 2023.
  • Sight Sciences' management team will host a conference call today, May 2, 2024, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Joby Partners with Abu Dhabi to Establish Electric Air Taxi Ecosystem

Retrieved on: 
목요일, 4월 25, 2024
Vehicle Technology, Automotive, Air, EV, Electric Vehicles, Transport, Alternative Vehicles, Fuels, Municipality, Smart, Memorandum of understanding, Ecosystem, Investment, Uber, Safety, Travel, Exhibition, Collaboration, GCAA, Yas Marina Circuit, Partnership, DMT, DED, SK Telecom, Joby Aviation, Aviation, Delta Air Lines, SAVI, JoeBen Bevirt, Multimedia, Government, Atmosphere, Economic development, Growth, Amusement park

Joby Aviation, Inc. (NYSE:JOBY), a company developing all-electric aircraft for commercial passenger service, today announced it has signed a multilateral Memorandum of Understanding (MoU) with the Department of Municipalities and Transport - Abu Dhabi (DMT), the Abu Dhabi Department of Economic Development (DED) and the Department of Culture and Tourism - Abu Dhabi (DCT Abu Dhabi) that lays the groundwork for Joby to establish and scale air taxi services in Abu Dhabi and beyond.

Key Points: 
  • Joby Aviation, Inc. (NYSE:JOBY), a company developing all-electric aircraft for commercial passenger service, today announced it has signed a multilateral Memorandum of Understanding (MoU) with the Department of Municipalities and Transport - Abu Dhabi (DMT), the Abu Dhabi Department of Economic Development (DED) and the Department of Culture and Tourism - Abu Dhabi (DCT Abu Dhabi) that lays the groundwork for Joby to establish and scale air taxi services in Abu Dhabi and beyond.
  • View the full release here: https://www.businesswire.com/news/home/20240425195449/en/
    departments to establish an electric air taxi ecosystem in the UAE.
  • The agreement also unlocks the potential for inter-emirate air taxi services, for example between Abu Dhabi and Dubai.
  • We’re looking forward to delivering a fantastic experience for our future customers in Abu Dhabi and we’re excited to be unlocking the potential for zero-emissions flight between Abu Dhabi and Dubai.

Additive Manufacturing in the Semiconductor Industry: New AM Research Report Sees $160M of Market Activity in 2024, Growing to $1.4B in 2032

Retrieved on: 
화요일, 4월 23, 2024
MBJ, PBF, Chips Act, 3D Systems, Geography, Microsoft Excel, Coherence, Research, DED, 3D printing processes, 3D, Semiconductor, Macro, Intel, Lam Research, BMD, Electronics, Research report, Applied Materials, ASML, Organization, 3D printing

NEW YORK, April 23, 2024 /PRNewswire/ -- Additive Manufacturing Research (AM Research) has published a new market study titled " 3D Printing for Semiconductors: Market Opportunity Brief ".

Key Points: 
  • NEW YORK, April 23, 2024 /PRNewswire/ -- Additive Manufacturing Research (AM Research) has published a new market study titled " 3D Printing for Semiconductors: Market Opportunity Brief ".
  • "3D Printing for Semiconductors" is packaged as a Market Opportunity Brief, the first in a new product series for AM Research.
  • Each Market Opportunity Brief is accompanied by an Excel file of historical market data as well as a 10-year forecast.
  • This report analyzes the state and outlook for additive manufacturing (AM) technologies to optimize and entrench into the semiconductor industry.

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

Retrieved on: 
화요일, 4월 9, 2024
Research, NCP, KOL, ARVO, DED, Pain, FDA

LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.

Key Points: 
  • LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.
  • The Company is rescheduling its event so that it can incorporate additional key analyses of its clinical data which it plans to present at upcoming ophthalmic conferences.
  • OKYO is planning to make a presentation at “Dry Horizons Symposium Navigating the Future of Dry Eye Research”, an event preceding the Association for Research in Vision and Ophthalmology (ARVO) conference with details provided below.

Verana Health Developing Qdata® Dry Eye Disease, the Largest Real-World Dataset of its Kind

Retrieved on: 
목요일, 4월 4, 2024
Prevalence, Dry eye syndrome, ASCRS, SAN, Patient, Ophthalmology, Research, RWD, American Academy, Cataract, DED, Society, Data, Telecanthus, Health, Annual general meeting, Nursing

Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.

Key Points: 
  • Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.
  • “We’re harnessing the power of real-world evidence to transform patient care and expedite the development of crucial therapies,” said Sujay Jadhav, CEO of Verana Health.
  • Dry eye disease affects nearly 16 million Americans , posing significant challenges for patients and ophthalmologists alike.
  • Verana Health remains at the forefront of this transformation, continuously expanding its Qdata offerings to meet the growing needs of life sciences teams and clinicians.

TearSolutions, Inc. Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors

Retrieved on: 
수요일, 4월 3, 2024
Principal, Harvard Medical School, Alpern, Public, Public health, FICS, Private practice, Telecanthus, Patient, DED, MPH, Therapy, FACS, Frustration, Ophthalmology, Pharmaceutical industry

“Dr.

Key Points: 
  • “Dr.
  • Alpern brings extensive real-world clinical experience treating patients with ocular surface disease, having prescribed or trialed virtually every dry eye treatment available,” said Anil Asrani, President and CEO of TearSolutions.
  • “Dr.
  • He received his Doctor of Medicine from Harvard Medical School and his Master of Public Health from the Harvard School of Public Health.

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
화요일, 4월 2, 2024
IOP, Gland, Signs, Ciclosporin, Glaucoma, LHT, Wills Eye Hospital, ASCRS, BCEC, Patient, Telecanthus, Meibomian gland dysfunction, Doctor of Philosophy, MD, GEMINI, DED, OMNI, Signs and symptoms, Safety, Poster, Pharmaceutical industry

MENLO PARK, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, announced today that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System (“OMNI”) and the TearCare System (“TearCare”), will be presented in two oral presentations and two posters at this year’s ASCRS Annual meeting April 5th to 8th in Boston, MA.

Key Points: 
  • OMNI technology facilitates surgeons’ ability to perform a comprehensive, implant-free, minimally invasive glaucoma surgical procedure in adults with primary open-angle glaucoma (“POAG”).
  • Lead author: Julio Echegoyen, MD, PhD
    Localized Heat Therapy (LHT) Compared to Cyclosporine Ophthalmic Emulsion (CsA): A Subanalysis on Age, Gender, and Disease Burden (SAHARA subanalysis) – poster presentation.
  • The event will be on Saturday, April 6, 2024, from 3:45 PM to 4:30 PM ET.
  • Learn more about this and other Sight Sciences activities at ASCRS at www.sightsciences.com/ascrs

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Retrieved on: 
화요일, 4월 2, 2024
NCP, Refractive surgery, ASCRS, Cataract, DED, Society, Pain, Telecanthus, FDA, Annual general meeting

LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

Key Points: 
  • LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Retrieved on: 
금요일, 3월 22, 2024
Day, Ora, Dry, NCP, Conjunctiva, BID, Physiology, Patient, Pain, Ophthalmology, Observation, Blurred Vision, Doctor of Philosophy, Itch, DED, MOA, Safety, Screen time, Telecanthus, Medical director, FDA, Pharmaceutical industry

Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.

Key Points: 
  • Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.
  • Tear Film Break-up Time showed statistically significant improvement as early as day 15 with the benefit durable for the remainder of the trial.
  • Burning/Stinging, and Blurred Vision improved as early as day 15 and the benefit remained durable throughout the trial.
  • Significant improvements were observed across multiple symptoms as measured in a daily symptom diary including pain, burning/stinging, eye dryness and itching within the first two weeks of treatment.

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Retrieved on: 
목요일, 3월 21, 2024
Visual Science, Uveitis, Wilmer Ophthalmological Institute, Brandeis University, Neurophysiology, NCP, BID, Telecanthus, Research, KOL, University, Patient, Doctor of Philosophy, Bascom Palmer Eye Institute, DED, Georgetown University Medical Center, Pain, Therapy, Johns Hopkins Hospital, Medical director, FDA, Pharmaceutical industry

LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be hosting a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss in depth the findings of the new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease, which will be announced on March 22nd, 2024.

Key Points: 
  • OKYO Pharma’s management team will also be in attendance to present an overview of OK-101’s mechanism of action.
  • He has published over 200 peer-reviewed articles and has served on the editorial boards of several prestigious ophthalmology journals.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The double-masked, randomized, placebo-controlled Phase 2 trial was conducted at six sites in the U.S. and enrolled 240 subjects with DED dosed twice-daily (BID).